| Summary |
|
||||||||||||||||
|
Transgene origin |
|
||||||||||||||||
|
Transgene description |
|
||||||||||||||||
|
Recombinase activity |
|
||||||||||||||||
| Phenotypes |
View phenotypes and curated references for all genotypes (concatenated display).
|
||||||||||||||||
| Disease models |
|
||||||||||||||||
| Tumor Data |
|
||||||||||||||||
| Find Mice (IMSR) |
|
||||||||||||||||
| Notes |
This transgenic line is one of seven founder lines expressing the transgene, as assessed by RT-PCR. Mice of each line were crossed to mice expressing a beta-galactosidase Cre reporter transgene. Following topical application of RU486, bitransgenic mice of lines 22, 42 and 49 were shown to exhibit beta-galactosidase activity in their skin. Line 22, which showed the least enzyme activity in untreated skin, was selected for further analysis.
|
||||||||||||||||
| References |
|
||||||||||||||||
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 09/30/2025 MGI 6.24 |
|
|
|
||